Why Is Steris (STE) Down 1.8% Since Last Earnings Report?

Steris (STE) shares have declined 1.8% in the past month, underperforming the S&P 500, with estimates trending downward leading to a Zacks Rank #3 (Hold) and expectation of in-line returns in the near term. In the same period, Pacific Biosciences of California (PACB), a peer in the Zacks Medical - Instruments industry, gained 11.3%, reporting revenues of $37.15 million (-4.3% year-over-year) and EPS of -$0.15, while anticipating a loss of $0.18 per share for the current quarter.

Analysis

Steris (STE) has experienced a 1.8% decline in its share price over the past month, underperforming the S&P 500, a trend accompanied by downward revisions in earnings estimates. The company currently holds Zacks VGM Scores of 'C' across Growth, Momentum, and Value, culminating in an overall 'C' grade, and is assigned a Zacks Rank #3 (Hold), suggesting expectations for in-line market performance in the near term. In contrast, Pacific Biosciences of California (PACB), a peer within the Zacks Medical - Instruments industry, has seen its stock appreciate by 11.3% during the same period. Pacific Biosciences recently reported revenues of $37.15 million for the quarter ended March 2025, a 4.3% decrease year-over-year, but demonstrated an improved EPS of -$0.15 compared to -$0.26 in the prior year. For the current quarter, PACB is projected to post a loss of $0.18 per share, which still represents a 10% positive year-over-year change, and its Zacks Consensus Estimate has risen by 1.4% over the last 30 days. Consequently, PACB holds a Zacks Rank #2 (Buy), though its VGM Score is 'D', indicating potentially weaker underlying fundamentals despite the positive estimate revisions and recent stock performance.

Key Decisions for Investors

• Investors holding Steris (STE) may consider maintaining their positions given its Hold rating, but should monitor upcoming earnings and analyst estimate revisions closely due to recent underperformance and downward estimate trends.
• Pacific Biosciences (PACB) presents a contrasting picture with recent stock gains and a Buy rating driven by upward estimate revisions, potentially offering a speculative opportunity, though its revenue decline and 'D' VGM score warrant careful risk assessment.
• The divergent trajectories of STE and PACB underscore the need for selective investment within the Medical - Instruments industry, emphasizing scrutiny of individual company estimate trends and fundamental scores rather than broad sector bets.